1-<3-(11-cyano-6,11-dihydrodibenzothiepin-11-yl)propyl>-4-(4-fluorophenyl)piperidin-4-ol | 99756-28-2

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 苯并硫平类
• 英文名称: 1-<3-(11-cyano-6,11-dihydrodibenzothiepin-11-yl)propyl>-4-(4-fluorophenyl)piperidin-4-ol
• 英文别名: LS374；11-[3-[4-(4-Fluorophenyl)-4-hydroxy-1-piperidinyl]propyl]-6,11-dihydrodibenzo[b,e]thiepin-11-carbonitrile；5-{3-[4-(4-Fluoro-phenyl)-4-hydroxy-piperidin-1-yl]-propyl}-5,11-dihydro-10-thia-dibenzo[a,d]cycloheptene-5-carbonitrile；11-[3-[4-(4-fluorophenyl)-4-hydroxypiperidin-1-yl]propyl]-6H-benzo[c][1]benzothiepine-11-carbonitrile
• CAS: 99756-28-2
• 化学式: C₂₉H₂₉FN₂OS
• 分子量: 472.626
• InChiKey: SYTQCBZULZYSSV-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  5.2
• 重原子数：
  34
• 可旋转键数：
  5
• 环数：
  5.0
• sp3杂化的碳原子比例：
  0.34
• 拓扑面积：
  72.6
• 氢给体数：
  1
• 氢受体数：
  5

反应信息

• 作为产物：
  描述：

  4-(4-氟苯基)-哌啶-4-醇盐酸盐 、 11-(2-bromopropyl)-6,11-dihydrodibenzothiepin-11-carbonitrile 在 potassium carbonate 作用下， 以 丙酮 为溶剂， 反应 10.0h， 以32%的产率得到1-<3-(11-cyano-6,11-dihydrodibenzothiepin-11-yl)propyl>-4-(4-fluorophenyl)piperidin-4-ol
  参考文献：
  名称：

  Potential antidiarrheal agents: 1-(11-Cyano-6,11-dihydrodibenzo[b,e]thiepin-11-yl-alkyl)- and 1-(10-cyano-10,11-dihydrodibenzo[b,f]thiepin-10-yl-alkyl)-4-substituted piperidines

  摘要：

  11-(2-溴乙基)-和11-(3-溴丙基)-6,11-二氢二苯并[be]噻吩-11-碳腈的取代反应，以及10-(2-溴乙基)-和10-(3-溴丙基)-10,11-二氢二苯并[bf]噻吩-10-碳腈与乙酸4-苯基哌啶-4-羧酸酯、4-苯基哌啶-4-醇、4-(2-甲苯基)哌啶-4-醇、4-(4-氟苯基)哌啶-4-醇、4-(2-氧代苯并咪唑啉-1-基)-哌啶和1-苯基-1,3,8-三氮杂螺[4,5]癸烷-4-酮的进一步反应，得到了三环哌啶烷基腈化合物IV-XIII，它们是抗腹泻药物地芬诺啶(I)和洛哌啶(III)的环式类似物。在制备的化合物中，只有IV和XI对小鼠静脉注射5-羟色胺引起的腹泻表现出显著的抑制作用。

  DOI：

  10.1135/cccc19851089

文献信息

• Methods of Inhibiting Metastasis from Cancer
  申请人：Salvino Joseph M.

  公开号：US20120141471A1

  公开（公告）日：2012-06-07

  The present invention includes compositions that are useful in preventing or treating metastasis in a subject diagnosed with cancer. The present invention also includes methods of preventing or treating metastasis in a subject diagnosed with cancer, wherein the method comprises administering to the subject in need thereof an effective amount of a pharmaceutical formulation comprising at least one pharmaceutically acceptable carrier and at least one CX 3 CR1 or fractalkine antagonist.

  本发明涉及一种用于预防或治疗被诊断为癌症的患者中的转移的组合物。本发明还包括一种用于预防或治疗被诊断为癌症的患者中的转移的方法，其中该方法包括向需要该药物的患者投与至少一种药用制剂，该制剂包括至少一种药用载体和至少一种CX3CR1或fractalkine拮抗剂的有效量。
• Compounds Useful for Inhibiting Metastasis from Cancer and Methods Using Same
  申请人：Drexel University College of Medicine Philadelphia Health & Education Corporation d/b/a

  公开号：US20130156761A1

  公开（公告）日：2013-06-20

  The present invention includes compositions that are useful in preventing or treating metastasis in a subject diagnosed with cancer. The present invention also includes methods of preventing or treating metastasis in a subject diagnosed with cancer, wherein the method comprises administering to the subject in need thereof an effective amount of a pharmaceutical formulation comprising at least one pharmaceutically acceptable carrier and at least one CX 3 CR1 or fractalkine antagonist.

  本发明涉及一种对已被诊断患有癌症的受试者预防或治疗转移的有用组合物。本发明还涉及一种预防或治疗已被诊断患有癌症的受试者的转移的方法，其中该方法包括向需要该药物的受试者施用至少一种药物制剂，该药物制剂包括至少一种药用载体和至少一种CX3CR1或fractalkine拮抗剂的有效量。
• Compounds useful for inhibiting metastasis from cancer and methods using same
  申请人：Drexel University

  公开号：US10414771B2

  公开（公告）日：2019-09-17

  The present invention includes compositions that are useful in preventing or treating metastasis in a subject diagnosed with cancer. The present invention also includes methods of preventing or treating metastasis in a subject diagnosed with cancer, wherein the method comprises administering to the subject in need thereof an effective amount of a pharmaceutical formulation comprising at least one pharmaceutically acceptable carrier and at least one CX3CR1 or fractalkine antagonist.

  本发明包括可用于预防或治疗确诊癌症患者转移的组合物。本发明还包括预防或治疗被诊断患有癌症的受试者的转移的方法，其中该方法包括向需要该方法的受试者施用有效量的药物制剂，该药物制剂包含至少一种药学上可接受的载体和至少一种CX3CR1或fractalkine拮抗剂。
• US8435993B2
  申请人：——

  公开号：US8435993B2

  公开（公告）日：2013-05-07
• US9375474B2
  申请人：——

  公开号：US9375474B2

  公开（公告）日：2016-06-28